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Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the
bone morphogenetic protein type 2 receptor (BMPR2), underlies most heritable forms of
PAH. To identify the missing heritability we perform whole-genome sequencing in 1038 PAH
index cases and 6385 PAH-negative control subjects. Case-control analyses reveal signiﬁcant
overrepresentation of rare variants in ATP13A3, AQP1 and SOX17, and provide independent
validation of a critical role for GDF2 in PAH. We demonstrate familial segregation of
mutations in SOX17 and AQP1 with PAH. Mutations in GDF2, encoding a BMPR2 ligand, lead
to reduced secretion from transfected cells. In addition, we identify pathogenic mutations in
the majority of previously reported PAH genes, and provide evidence for further putative
genes. Taken together these ﬁndings contribute new insights into the molecular basis of PAH
and indicate unexplored pathways for therapeutic intervention.
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Idiopathic and heritable pulmonary arterial hypertension(PAH) are rare disorders characterised by occlusion ofarterioles in the lung1, leading to marked increases in
pulmonary vascular resistance2. Life expectancy from diagnosis
averages 3–5 years3, with death ensuing from failure of the right
ventricle.
Mutations in the gene encoding the bone morphogenetic
protein type 2 receptor (BMPR2), a receptor for the transforming
growth factor-beta (TGF-β) superfamily4,5 account for over 80%
of families with PAH, and approximately 20% of sporadic cases6.
Mutations have been identiﬁed in genes encoding other compo-
nents of the TGF-β/bone morphogenetic protein (BMP) signal-
ling pathways, including ACVRL17 and ENG8. On endothelial
cells, BMPR2 and ACVRL1 form a signalling complex, utilising
ENG as a co-receptor. Case reports of rare sequence variation in
the BMP signalling intermediaries, SMAD1, SMAD4 and
SMAD99,10, provide compelling evidence for a central role of
dysregulated BMP signalling in PAH pathogenesis.
Analysis of coding variation in BMPR2-negative kindreds
revealed heterozygous mutations in genes not directly
impacting on the TGF-β/BMP pathway, including CAV111, and
the potassium channel, KCNK312. Deletions and loss of function
mutations in TBX4, an essential regulator of embryonic
development, were identiﬁed in childhood-onset PAH13. A
clinically and pathologically distinct form of PAH, known as
pulmonary veno-occlusive disease or pulmonary capillary
haemangiomatosis (PVOD/PCH), was shown recently to be
caused by biallelic recessive mutations in EIF2AK414,15, a kinase
in the integrated stress response.
The purpose of the present study was to identify additional rare
sequence variation contributing to the genetic architecture of
PAH, and to assess the relative contribution of rare variants in
genes implicated in prior studies. A major ﬁnding is that rare
likely causal heterozygous variants in several previously uni-
dentiﬁed genes (ATP13A3, AQP1 and SOX17) were signiﬁcantly
overrepresented in the PAH cohort, and we provide independent
validation for GDF2 as a causal gene.
Results
Description of the PAH cohort. In total, 1048 PAH cases (1038
index cases and 10 related affected individuals) were recruited for
WGS. Of these, 908 (86.7%) were diagnosed with idiopathic PAH,
58 (5.5%) gave a family history of PAH and 60 (5.7%) gave a
history of drug exposure associated with PAH16. Twenty two
cases (2.1%) held a clinical diagnosis of PVOD/PCH (Fig. 1a).
Demographic and clinical characteristics of the PAH cohort are
provided in Supplementary Table 1. An additional UK family was
recruited separately for novel gene identiﬁcation studies. Brieﬂy,
the proband was diagnosed at 12 years with a persistent ductus
arteriosus and elevated pulmonary arterial pressure. Explant lung
histology following heart-lung transplantation revealed the pre-
sence of plexiform lesions. Two of the proband’s offspring were
also diagnosed with childhood-onset PAH, one of which had an
atrial septal defect. The proband’s parents, siblings and a third
child showed no evidence of cardiovascular disease.
Pathogenic variants in previously reported PAH disease genes.
Our ﬁltering strategy detected rare deleterious variation in pre-
viously reported PAH genes in 19.9% of the PAH cohort. For
BMPR2, rare heterozygous mutations were identiﬁed in 160 of
1048 cases (15.3%). The frequency of BMPR2 mutations in
familial PAH was 75.9%, in sporadic cases 12.2%, and 8.3% in
anorexigen-exposed PAH cases. Forty-eight percent of BMPR2
mutations were reported previously17, and the remainder were
newly identiﬁed in this study. Fourteen percent of BMPR2
mutations resulted in the deletion of larger protein-coding
regions ranging from 5 kb to 3.8 Mb in size. Supplementary
Data 1 provides the breakdown of BMPR2 SNVs and indels, and
the larger deletions are shown in Fig. 2a–c with a detailed sum-
mary in Supplementary Table 2.
Of the other genes previously reported in PAH we identiﬁed
deleterious heterozygous rare variants in ACVRL1 (9 cases, 0.9%),
ENG (6 cases, 0.6%), SMAD9 (4 cases, 0.4%), KCNK3 (4 cases,
0.4%), and TBX4 (14 cases, 1.3%). We identiﬁed one case with
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Fig. 1 Flow diagrams illustrating a the composition of the NIHR BioResource—Rare Diseases (NIHR BR-RD) PAH study and b the analysis strategy to
identify novel PAH disease genes. a The study comprised 1048 adult cases (aged 16 or over) attending specialist pulmonary hypertension centres from the
UK (n= 731), and additional cases from France (n= 142), The Netherlands (n= 45), Germany (n= 82) and Italy (n= 48). b A series of case-control
comparisons including and excluding cases with variants in previously reported disease genes were undertaken using complementary ﬁltering strategies
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Fig. 2 Analysis of copy number deletions. a Deletions affecting the BMPR2 locus in 23 PAH cases. Genes are indicated in orange and labelled with their
respective gene symbol. Deletions are drawn as blue boxes above the genome axis (grey) showing the genomic position on chromosome 2. The grey box
highlights the location of BMPR2. b Locus zoom on BMPR2 highlighting the focal deletions affecting one or more exons. c WGS coverage proﬁles of a
selected set of smaller and larger deletions, visualised with the Integrative Genomics Viewer (IGV)57, with deletions highlighted by red bars. d and e
Manhattan plots of the genome-wide case-control comparison of large deletions. In d, all subject are considered. In e, subject with larger deletions affecting
the BMPR2 locus are excluded. The adjusted P value threshold of 5 × 10−8 for genome-wide signiﬁcance is indicated by the red line
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highly deleterious variants in both BMPR2 (p.Cys123Arg) and
SMAD9 (p.Arg294Ter). Details of consequence types, deleter-
iousness and conservation scores, and minor allele frequencies are
provided in Supplementary Data 2. Fourteen cases (1.3%) with
biallelic EIF2AK4 mutations were found18. No pathogenic coding
variants in CAV1, SMAD1 or SMAD4 were identiﬁed. Taken
together, rare causal variation in non-BMPR2 disease genes
(TBX4, ENG, ACVRL1, SMAD9, KCNK3 and EIF2AK4)
accounted for 4.7% of the entire PAH cohort. The clinical
characteristics of cases with variants in these previously reported
genes are shown in Supplementary Table 3.
In a case-control comparison of the frequencies of deleterious
variants conﬁned to the previously reported PAH genes, we
observed signiﬁcant overrepresentation of rare variants in
BMPR2, TBX4, ACVRL1 and biallelic variants in EIF2AK4 only
(P < 0.05; Supplementary Table 4).
Identiﬁcation of novel PAH disease genes. The strategy to
identify novel causative genes in PAH employed a series of case-
control analyses (Fig. 1b). To identify signals that might be
masked by variants in previously reported PAH genes, we
excluded subjects with rare variants and deletions in BMPR2,
EIF2AK4, ENG, ACVRL1, TBX4, SMAD9 and KCNK3. A
genome-wide comparison of protein-truncating variants (PTVs),
representative of high impact variants, identiﬁed a higher fre-
quency of PTVs in ATP13A3 (six cases) (Padj= 0.0346). More-
over, we identiﬁed additional PTVs in several putative PAH
genes, including EVI5 (5 cases, 1 control) and KDR (4 cases, 0
controls; Fig. 3a), that require further validation to evaluate their
contribution to PAH pathogenesis (Supplementary Table 5).
We next analysed rare missense variants overrepresented in the
PAH cohort, again excluding subjects with variants in the
previously reported PAH genes. This revealed signiﬁcant over-
representation of rare variants in GDF2 after correction for
multiple testing (Padj= 0.0023), followed by AQP1 (Fig. 3b and
Supplementary Table 6). Next, in a combined analysis of rare
missense variants and PTV, only GDF2 remained signiﬁcant
(P= 0.001). Rare variants in additional putative genes occurred at
higher frequency in cases compared to controls, including AQP1,
ALPPL2, ATP13A3, OR8U1, IFT74, FLNA, SOX17, ATP13A5,
C3orf20 and PIWIL1 (uncorrected P value < 0.0005), but were not
signiﬁcant after correction for multiple testing (Fig. 3c and
Supplementary Table 7).
In order to increase power to detect rare associations, we
deployed SKAT-O on ﬁltered rare PTVs and missense variants.
Excluding previously reported genes, this analysis revealed an
association with rare variants in AQP1 (Padj= 4.28 × 10−6) and
SOX17 (Padj= 6.7 × 10−5; Fig. 3d). AQP1 and SOX17 were both
also nominally signiﬁcant in the combined burden tests, described
above. Association was also found with rare variants in MFRP
(Padj= 1.3 × 10−5). However, we consider MFRP a false-positive
ﬁnding for reasons given in the Discussion. Supplementary
Table 8 shows the top 50 most signiﬁcant genes identiﬁed by
SKAT-O, providing further candidates to be evaluated in future
studies. Details of rare variants in novel PAH genes (GDF2,
ATP13A3, AQP1, SOX17) identiﬁed in cases are provided in
Supplementary Data 3.
Notably, a genome-wide assessment of larger structural
variation did not identify any additional large deletions
after exclusion of subjects harbouring deletions in BMPR2
(Fig. 2d, e).
The proportion of PAH cases with mutations in the new genes
was 3.5%. The clinical characteristics of PAH cases with
mutations in these genes are provided in Supplementary Table 3b.
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Fig. 3Manhattan plots of the rare variant analyses, having excluded cases carrying rare variants in previously established PAH genes. Filtered variants were
grouped per gene. We tested for an excess of variants in PAH cases within genes using Fisher’s exact test. The negative decadic logarithm of unadjusted or
adjusted P-values are plotted against the chromosomal location of each gene. a Burden test of rare PTVs. b Burden test of rare deleterious missense
variants. c Burden test combining rare PTVs and likely deleterious missense variants. d SKAT-O test of rare PTVs and missense variants
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Of note, cases with mutations in SOX17 and AQP1 were
signiﬁcantly younger at diagnosis (32.8 ± 16.2 years (P= 0.002)
and 36.9 ± 14.3 years (P= 0.013), respectively) compared to cases
with no mutations in the previously established genes (51.7 ± 16.6
years).
Non-coding variation around PAH disease genes. An initial
analysis for enrichment of variants in the non-coding sequence
surrounding previously reported and newly identiﬁed PAH dis-
ease genes, including upstream gene regions, 5’ UTRs, intronic
sequence, 3’ UTRs and downstream gene regions, did not detect
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Fig. 4 Pedigree structures and analysis of familial transmission of variants in AQP1 and SOX17. a Individual II.1 harbours a heterozygous de novo SOX17
c.411 C > G (p.Y137*) PTV resulting in a premature termination codon, which has been transmitted to the affected male (III.1). No unaffected family
members carry the variant. No sample was available from subject III.2. b Proband E011942 has inherited a heterozygous AQP1 c.583 C > T (p.R195W)
missense variant from her affected father. No sample was available from the affected sister of the proband. The younger healthy uncle of the index case
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an signiﬁcant overrepresentation in the PAH cohort. Details of
the non-coding variants that passed the ﬁltering strategy are
provided in Supplementary Data 4.
Independent validation and familial segregation analysis. To
provide further validation of the potentially causal role of
mutations in the new genes identiﬁed, we examined whole-exome
data from an independent UK family with three affected indivi-
duals across two generations. Microsatellite genotyping across
chromosome 2q33 had previously demonstrated non-sharing of
haplotypes in affected individuals, consistent with exclusion of
linkage to the BMPR2 locus. No pathogenic variants were iden-
tiﬁed in the protein-coding regions of the BMPR2 gene or other
TGF-β pathway genes. Analysis of exome sequence data from
individual II-1 identiﬁed a novel heterozygous c.411 C > G (p.
Y137*) PTV in the SOX17 gene. Segregation analysis in the
extended family demonstrated that the mutation had arisen de
novo in the affected father (II-1) and was transmitted to the
affected offspring (III-1). All unaffected family members were
conﬁrmed as wild-type (Fig. 4a).
Three HPAH subjects harbouring rare variants in AQP1,
identiﬁed in the NIHR BR-RD WGS study, were also selected for
familial co-segregation analysis (Fig. 4b–d). No pathogenic
variants in any of the previously reported genes were identiﬁed
in these families. The ﬁrst pedigree comprised three affected
individuals across two generations. Sanger sequencing conﬁrmed
the presence of the heterozygous AQP1 c.583 C > T (p.R195W)
missense variant in the proband (E011942), the affected father
(E011942.f) and the healthy younger paternal uncle (E011942.u1).
An additional unaffected uncle did not carry the AQP1 variant.
These results indicate likely incomplete penetrance in the
unaffected carrier, as observed in BMPR2 families19. No
additional clinical information was available for the deceased
grandparents (Fig. 4b). The remaining two families comprised
affected parent-offspring individuals. By Sanger sequencing we
independently conﬁrmed a heterozygous AQP1 c.527 T > A (p.
Val176Glu) missense variant in proband (E012415) and his
affected father (Fig. 4c), as well as a heterozygous AQP1 c.583 C >
T (p.R195W) missense variant in proband (E010634) and her
affected father (Fig. 4d). These results highlight recurrent AQP1
variation across unrelated families and demonstrate co-
segregation with the phenotype.
Predicted functional impact of variants in novel PAH genes. To
evaluate the potential functional impact of rare variants identiﬁed
in the likely causative new genes we performed structural analysis
of GDF2, ATP13A3, AQP1, and SOX17. In addition we undertook
a functional analysis of the GDF2 variants identiﬁed.
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Fig. 5 Structural analysis of GDF2 mutations. a Schematic diagram of GDF2 processing. The pre-pro-protein is processed into the mature growth factor
domain (GFD) bound to the prodomain upon secretion61. b Plot of GDF2 mutations found only in PAH cases superimposed on the structure of prodomain
bound GDF2 (PDB: 4YCG)21. The GDF2 growth factor domain is shown in green and the prodomain in cyan. c Magniﬁed view of the Arg110 and Glu143
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Heterozygous mutations in GDF2 exclusive to PAH cases
comprised 1 frameshift variant and 7 missense variants. GDF2
encodes growth and differentiation factor 2, also known as bone
morphogenetic protein 9 (BMP9), the major circulating ligand for
the endothelial BMPR2/ACVRL1 receptor complex20. Amino
acid substitutions were assessed against the published crystal
structure21 of the prodomain bound form of GDF2 (Fig. 5).
Variants clustered at the interface between the prodomain and
growth factor domain. Since the prodomain is important for the
processing of GDF2, it is likely that amino acid substitutions
reduce the stability of the prodomain-growth factor interface. In
keeping with these predictions, HEK293T cells transfected with
GDF2 variants exclusive to PAH cases, demonstrated reduced
secretion of mature GDF2 into the cell supernatants (Fig. 5d),
compared with wild-type GDF2.
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Fig. 6 Structural analysis of ATP13A3 mutations. a Topology of ATP13A3, plotted according to UniProtKB Q9H7F0. Frameshift and stop-gained mutations
identiﬁed in PAH cases are shown as khaki circles, and missense mutations as red circles. Frameshift/stop-gained mutations are predicted to truncate the
protein prior to the catalytic domain and essential Mg binding sites, leading to loss of ATPase activity. b Sequence alignment of ATP13A3 with ATP1A1
(P05024), of which the high resolution structure was used for the structural analysis in c. The conserved regions of ATP13A3 and ATP1A1, essential for
ATPase activity62, show good alignment (data not shown). Only regions containing the missense PAH mutations are shown, with positions of the four
missense mutations highlighted in yellow above the sequences. c Structural analysis of the 4 PAH missense mutations plotted on the ATP1A1 crystal
structure based on the sequence alignment in b (PDB: 3wgu)63. Green: α subunit (P05024), cyan: β subunit (P05027), grey: γ-subunit transcript variant a
(Q58k79). Y535, Y677, R685 and I787 are the numbering in ATP1A1. Positions of the four missense mutations found in PAH are labelled and highlighted
by red circles. d Magniﬁed view of the cytoplasmic region of the ATPase, showing the presence of ADP at the active site. The conserved regions essential
for ATPase activity are shown in light pink. The L675V and R858H mutations are located close to the ATP catalytic region
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We identiﬁed three heterozygous frameshift variants, two stop
gained, two splice region variants in ATP13A3, which are
predicted to lead to loss of ATPase catalytic activity (Fig. 6a).
In addition, we identiﬁed 4 heterozygous likely pathogenic
missense variants in PAH cases, two near the conserved ATPase
catalytic site and predicted to destabilise the conformation of the
catalytic domain (Fig. 6b–d). The distribution of variants (Fig. 6a)
suggests that these mutations impact critically on the function of
the protein.
The majority of rare variants identiﬁed in AQP1, which
encodes aquaporin-1, are situated within the critical water
channel (Fig. 7). In particular the p.Arg195Trp variant, identiﬁed
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Q6PQZ1|AQP1_PIG        LPGNSLGLNSLAPGVDSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGFSVA
Q9N2J4|AQP1_CANLF      LPDNSLGRNELAPGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSGPLAIGLSVA
P47865|AQP1_BOVIN      LPDNSLGLNALAPGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSGPLAIGFSVA
P56401|AQP1_SHEEP      LPDNSLGLNALAPGVNSGQGLGIEIIGTLQLVLCVLATTDRRRRRDLGDSGPLAIGFSVA
                      *  **** * ** **:************************** *****.*.*****:***
P29972|AQP1_HUMAN      LGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD
Q5R819|AQP1_PONAB      LGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD
Q02013|AQP1_MOUSE      LGHLLAIDYTGCGINPARSFGSAVLTRNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD
P29975|AQP1_RAT        LGHLLAIDYTGCGINPARSFGSAVLTRNFSNHWIFWVGPFIGSALAVLIYDFILAPRSSD
Q6PQZ1|AQP1_PIG        LGHLLAIDYTGCGINPARSFGSAVITHNFQDHWVFWVGPFIGGALAVLIYDFILAPRSSD
Q9N2J4|AQP1_CANLF      LGHLLAIDYTGCGINPARSFGSSVITHNFKDHWIFWVGPFIGGALAVLIYDFILAPRSSD
P47865|AQP1_BOVIN      LGHLLAIDYTGCGINPARSFGSSVITHNFQDHWIFWVGPFIGAALAVLIYDFILAPRSSD
P56401|AQP1_SHEEP      LGHLLAIDYTGCGINPARSFGSSVITHNFQDHWIFWVGPFIGAALAVLIYDFILAPRSSD
                      **********************:*:*:**.:**:********.*****************
a
Fig. 7 Structural analysis of AQP1 mutations. a Multiple sequence alignment of human AQP1 with seven other mammals. The bovine AQP1 has the high
resolution (2.2 Å) published structure. Mutations identiﬁed in PAH cases are highly conserved and highlighted in yellow. b Crystal structure of bovine AQP1
(PDB: 1j4n)22. Left: side view; right: top view from the extracellular direction. AQP1 is shown as a semi-transparent cartoon and ﬁve water molecules in the
water channel are shown as red spheres. Key residues lining the water channels are represented with stick structures. cMagniﬁed view of the water channel,
with H-bonds connected to water molecules in the channel highlighted. Two asparagine-proline-alanine (NPA) motifs, essential for the water transporting
function of AQP1, are shown in magenta. Conserved His180 that constricts the water channel is shown in yellow. Mutations found in PAH cases, Arg195Trp
and Val176Glu, are labelled and shown as orange stick structures. Arg195 and His180 are highly conserved in the known water channels and are strong
indicators of water channel speciﬁcity. Arg195Trp and Val176Glu mutations are predicted to disrupt the conformation of this conserved water channel
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in ﬁve PAH cases, locates at the hydrophilic face of the pore. This
arginine at position 195 helps deﬁne the constriction region of the
AQP1 pore structure and is conserved across the water-speciﬁc
aquaporins22. Rare variants in SOX17, included four nonsense
variants (including the PTV identiﬁed in the additional UK
family) predicted to lead to loss of the beta-catenin binding
region, and six missense variants predicted to disrupt interactions
with Oct4 and beta-catenin23,24 (Fig. 8).
GDF2 is known to be secreted from the liver, but the cellular
localisation of proteins encoded by the other novel genes is less
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P48431|SOX2_HUMAN   SRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRALHMKEHPDYKYR
P57073|SOX8_HUMAN   AQAARRKLADQYPHLHNAELSKTLGKLWRLLSESEKRPFVEEAERLRVQHKKDHPDYKYQ
Q9H6I2|SOX17_HUMAN   AKDERKRLAQQNPDLHNAELSKMLGKSWKALTLAEKRPFVEEAERLRVQHMQDHPNYKYR
P35713|SOX18_HUMAN   AKDERKRLAQQNPDLHNAVLSKMLGKAWKELNAAEKRPFVEEAERLRVQHLRDHPNYKYR
           :: *:::*:: *.:**: :** ** *: *. :*****::**:***. * ::**:***:
P48431|SOX2_HUMAN   PRRKTKTLMKKDKYTLPGGLLAPG---------------GNSMASGVGVGAGLGAGVNQR
P57073|SOX8_HUMAN   PRRRKSAKAGH---SDSDSG----------AELGPHPGGGAVYKAEAGLGDGHHHGDHTG
Q9H6I2|SOX17_HUMAN   PRRRKQVKRLK---RVEGGFLH-GLAEPQAAALGPE--GGRVAMD--GLGLQFP---EQG
P35713|SOX18_HUMAN   PRRKKQARKAR---RLEPGLLLPGLAPPQPPP--------------------------EP
           ***:... :   .                     
P14859|PO2F1_HUMAN   LPQSQSTPK-RI---DTPSLEEPSDLEELEQFAKTFKQRRIKLGFTQGDVGLAMGKLYGN
Q01860|PO5F1_HUMAN   TPGAVKLEKEKLEQNPEESQDIKALQKELEQFAKLLKQKRITLGYTQADVGLTLGVLFGK
           * : . * ::   * : : :******* :**:**.**:**.****::* *:*:
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172
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Fig. 8 Structural analysis of SOX17 mutations. a Schematic diagram of human SOX17 (Q9H6I2), based on UniProtKB annotation, and published reports23.
Red arrows indicate PTVs and black arrows indicate missense mutations identiﬁed in PAH patients. The blue bar illustrates the region that is covered in the
crystal structure (PDB: 3F27)64. The ability of SOX17 to activate transcription of target genes correlates with binding to β-catenin23. As illustrated, all PTVs
lead to a loss of the β-catenin binding region. Two missense mutations are located within and very close to the minimum β-catenin binding regions, and
both are highly conserved, indicating they are likely to be important for β-catenin binding. b Structural analysis of HMG domain missense mutations found
in PAH patients. Left, Superposition of SOX17/DNA structure (Sox17: cyan, DNA: grey)64 onto SOX2/DNA/Oct1 structure (PDB: 1GT0, Sox2: yellow, Oct1:
magenta, DNA: light blue)24. Right: Magniﬁed view of the interactions around Arg140 in the SOX2/DNA/Oct structure. Arg140 in SOX2 makes multiple
H-bond interactions and mutating this Arg in SOX2 abolishes the interaction with transcription factors Pax6 and Oct424. SOX2 and SOX17 both bind to
Oct465 and SOX17 K122E mutant can replace SOX2 in maintaining stem cell pluripotency65, indicating this region in SOX17 may interact with Oct4, similar
to SOX2. The three missense mutations in SOX17 will likely disrupt interaction with Oct4. c Supporting the analysis in b, sequence alignment shows that the
HMG domain of SOX2 (P48431) and SOX17 as well as SOX8 (P57073) and SOX18 (P35713) share high sequence identity and the three mutations found in
PAH (highlighted in yellow) are highly conserved emphasising their functional importance. Similarly, the Gly and Thr that interact with Arg140 in SOX2
(highlighted in yellow) are also conserved between Oct1 (PO2F1) and Oct4 (PO5F1)
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well characterised. Thus we employed immunohistochemistry to
examine localisation in the normal and hypertensive human
pulmonary vasculature. Figure 9 shows that AQP1, ATP13A3 and
SOX17 are predominantly localised to the pulmonary endothe-
lium in normal human lung and to endothelial cells within
plexiform lesions of patients with idiopathic PAH. In addition, we
determined the relative mRNA expression levels of AQP1,
ATP13A3 and SOX17 in primary cultures of pulmonary artery
smooth muscle cells (PASMCs), pulmonary artery endothelial
cells (PAECs) and blood outgrowth endothelial cells (BOECs)25.
AQP1 was expressed in PASMCs and endothelial cells, with a
trend towards higher levels in PASMCs (Fig. 10a). ATP13A3 was
highly expressed in both cell types (Fig. 10b), whereas SOX17 was
almost exclusively expressed in endothelial cells (Fig. 10c).
Although AQP1 and SOX17 are known to play roles in
endothelial function, the function of ATP13A3 in vascular cells
is entirely unknown. Thus, we determined the impact of
ATP13A3 knockdown on proliferation and apoptosis of BOECs.
Loss of ATP13A3 led to marked inhibition of serum-stimulated
proliferation of BOECs, and increased apoptosis in serum-
deprived conditions (Fig. 10d–f).
Discussion
We report a comprehensive analysis of rare genetic variation in a
large cohort of index cases with idiopathic and heritable forms of
PAH. Whilst we utilised WGS, the main goal was the identiﬁ-
cation of rare causal variation underlying PAH in the protein-
coding sequence. The approach involved a rigorous case-control
comparison using a tiered search for variants. First, we searched
for high impact PTVs overrepresented in cases, having excluded
previously established PAH genes. This revealed PTVs in
ATP13A3, a poorly characterised P-type ATPase of the
P5 subfamily26. There is little information regarding the function
of the ATPase, ATP13A3, which appears widely expressed in
mouse tissues26. Although, the precise substrate speciﬁcity is
unknown, ATP13A3 plays a role in polyamine transport27. Based
on available RNA sequencing data, ATP13A3 is highly expressed
in human pulmonary vascular cells and cardiac tissue (https://
www.encodeproject.org). We conﬁrmed that ATP13A3 mRNA is
expressed in primary cultured pulmonary artery smooth muscle
cells and endothelial cells, and provide preliminary data that loss
of ATP13A3 inhibits proliferation and increases apoptosis of
endothelial cells. These ﬁndings are consistent with the widely
b c
e f
h i
d
g
j
a
Concentric lesion
Plexiform lesion
Fig. 9 Immunolocalisation of AQP1, ATP13A3 and SOX17 in normal and PAH lung. The typical histological ﬁndings (haematoxylin and eosin staining) of
concentric vascular lesions with associated plexiform lesions are shown (a). Higher magniﬁcation images of plexiform lesion (b), with frequent
endothelialised channels (c; anti-CD31) surrounded by myoﬁbroblasts (d; anti-SMα). Additional high magniﬁcation images demonstrating endothelial
expression of ATP13A3 (e), AQP1 (f) and SOX17 (g) in PAH lung. Controls lung sections demonstrating predominantly endothelial expression of ATP13A3
(h), AQP1 (i) and SOX17 (j). (Scale bars= 50 µm)
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accepted paradigm that endothelial apoptosis is a major trigger
for the initiation of PAH28,29. It will be of considerable interest to
determine the role of ATP13A3 in vascular cells and whether it is
functionally associated with BMP signalling, or represents a dis-
tinct therapeutic target in PAH.
Analysis of missense variation, and a combined analysis of all
predicted deleterious variation, revealed that mutation at the
GDF2 gene is also signiﬁcant determinant of predisposition to
PAH. Of the new genes identiﬁed, GDF2 provides further evi-
dence for the central role of the BMP signalling pathway in PAH.
GDF2 encodes the major circulating ligand for the endothelial
BMPR2/ACVRL1 receptor complex20. Taken together, the
genetic ﬁndings suggest that a deﬁciency in GDF2/BMPR2/
ACVRL1 signalling in pulmonary artery endothelial cells is cri-
tical in PAH pathobiology. The majority of GDF2 variants
detected in our adult-onset PAH cohort were heterozygous mis-
sense variants, in contrast to a previous case report of childhood-
onset PAH due to a homozygous nonsense mutation30. The
ﬁnding of causal GDF2 variants in PAH cases, associated with
reduced production of GDF2 from cells, provides further support
for investigating replacement of this factor as a therapeutic
strategy in PAH31.
To maximise the assessment of rare variation in a case-control
study design, we deployed the SKAT-O test. This approach
revealed a signiﬁcant association of rare variation in the aqua-
porin gene, AQP1, and the transcription factor encoded by
SOX17. Of note, both AQP1 and SOX17 were within the top 8
ranked genes in our combined PTV and missense burden test
analysis (Supplementary Table 7), providing further conﬁdence in
their causative contribution to PAH.
Aquaporin-1 belongs to a family of membrane channel pro-
teins that facilitate water transport in response to osmotic gra-
dients22, and AQP1 is known to promote endothelial cell
migration and angiogenesis32. Thus, approaches that maintain or
restore pulmonary endothelial function could offer new ther-
apeutic directions in PAH. Conversely, AQP1 inhibition in pul-
monary artery smooth muscle cells ameliorated hypoxia-induced
pulmonary hypertension in mice33, suggesting that further studies
are required to determine the key cell type impacted by AQP1
mutations in human PAH, and the functional impact of these
AQP1 variants on water transport. The demonstration of familial
segregation of AQP1 variants with PAH provides further support
for the potentially causal role of these mutations in disease.
However, we also identiﬁed an unaffected AQP1 variant carrier
consistent with reduced penetrance, which is well described for
other PAH genes, including BMPR2.
Although functional studies are required to conﬁrm the
mechanisms by which mutations in SOX17 cause PAH, this
ﬁnding provides additional support for the vascular endothelium
as the major initiating cell type in this disorder. SOX17 encodes
the SRY-box containing transcription factor 17, which plays a
fundamental role in angiogenesis34 and arteriovenous
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Fig. 10 Functional studies of novel genes. a–c Expression of a AQP1, b ATP13A3 and c SOX17 mRNA in human pulmonary artery smooth muscle cells,
pulmonary artery endothelial cells and blood outgrowth endothelial cells (BOECs) (n= 4 biological replicates of each). Relative expression of each
transcript was normalised to three reference genes, ACTB, B2M and HPRT. d Proliferation of BOECs in 5% FBS over 6 days. Cells were transfected with
DharmaFECT1 alone (DH1), siATP13A3 or non-targeting siRNA control (siCP) e, f Quantiﬁcation of apoptosis in BOECs, deﬁned as Annexin V+/PI− cells,
in BOECs transfected with siATP13A3 or siCP in complex with DH1 followed by 24 h treatment with 0.1% FBS or 5% FBS (n= 4 biological repeats). f
Measurement of apoptosis via Caspase-Glo 3/7 activity measurements in BOECs transfected with siATP13A3 or siCP in complex with DH1, followed by 16
h treatment in 0.1% FBS or 5% FBS. Data are from a single experiment (n= 4 wells) representative of 3 biological repeats. Data were analysed using a
One-way analysis of variance with post hoc Tukey’s test for multiple comparisons in d and f. Data were analysed using a repeated measures One-way
analysis of variance with post hoc Tukey’s for multiple comparisons in e. *P < 0.05, **P < 0.01 within treatment groups. ###P < 0.001 for effect of ligand
against control for same transfection condition
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differentiation35. Moreover, conditional deletion of SOX17 in
mesenchymal progenitors leads to impaired formation of lung
microvessels36. The demonstration of familial segregation of the
SOX17 p.Y137* PTV with early onset PAH provides additional
evidence for a causal role for these variants in PAH. The co-
existence of a patent ductus arteriosus in the index case and an
atrial septal defect (ASD) in one of the affected offspring is of
interest and suggests an association with congenital heart disease.
Small ASDs are not uncommon in idiopathic PAH, and a more
detailed clinical phenotyping of SOX17 mutation carriers will be
required to determine whether the presence of ASDs and other
congenital heart abnormalities are more common in carriers of
these mutations.
Whilst the SKAT-O analysis also provided support for the
MFRP gene, recessive biallelic mutations in MFRP cause retinal
degeneration and posterior microphthalmos37. The expression of
MFRP transcripts is largely conﬁned to the central nervous sys-
tem38 and the majority of variants were present in the Genome
Aggregation Database (GnomAD, http://gnomad.broadinstitute.
org). On the basis of these considerations, variants in MFRP are
unlikely to contribute to PAH aetiology.
This analysis provides new insights on the frequency and
validity of previously reported genes in PAH. We conﬁrmed that
mutations in BMPR2 are the most common genetic cause and
validated rare causal variants in ACVRL1, ENG, SMAD9, TBX4,
KCNK3 and EIF2AK4. Although our ﬁndings question the
validity of CAV1, SMAD1 and SMAD4 as causal genes, previous
reports might represent private mutations occurring in very rare
families. The use of WGS in this study allowed closer inter-
rogation of larger deletions around the BMPR2 locus than has
been possible previously. Nevertheless, additional analyses are
required to determine the full impact of structural variation
(inversions, duplications, smaller deletions) at this and other loci.
The non-PAH cohort used in the case-control comparisons for
this study comprised individuals, or relatives of individuals, with
other rare diseases recruited to the NIHR BR-RD in the UK
(Methods section). In general, for very rare causal variants, the
comparison between PAH cases and non-PAH rare disease
controls should not reduce our ability to detect over-
representation of rare variants in a particular gene in the PAH
cohort, if mutations in that gene are speciﬁc to PAH. However, if
rare variants in a gene were responsible for more than one phe-
notype, it is possible that this would reduce the power to detect
overrepresentation in the PAH cohort. For example, if mutations
occurred in different functional domains of the expressed protein,
this might lead to PAH if mutations affected one domain, but
other phenotypes if they affected another domain. Overcoming
this potential limitation will require additional analysis of the
functional impact of variants and their distribution within a gene,
and more detailed information on the phenotypes of subjects in
the non-PAH group.
Taken together, this study identiﬁes rare sequence variation in
new genes underlying heritable forms of PAH, and provides a
unique resource for future large-scale discovery efforts in this
disorder. Mutations in previously established genes accounted for
19.9% of PAH cases. Including new genes identiﬁed in this study
(GDF2, ATP13A3, AQP1, and SOX17), the total proportion of
cases explained by mutations increased to 23.5%. It is likely that
independent conﬁrmation of the expanded list of putative genes
identiﬁed in this study will increase further the proportion of
cases explained by mutations, but this will require larger inter-
national collaborations. The results suggest that the genetic
architecture of PAH, beyond mutations in BMPR2, is char-
acterised by substantial genetic heterogeneity and consists of rare
heterozygous coding region mutations shared by small numbers
of cases. The contribution of rare variation within non-coding
regulatory regions to PAH aetiology remains to be determined.
This will require functional annotation of regulatory and other
non-coding regions speciﬁc for relevant cell types, further case-
control analyses of these regions and ultimately functional studies
of gene regulation to assess the pathogenicity of non-coding
variants. Our ﬁndings to date provide support for a central role of
the pulmonary vascular endothelium in disease pathogenesis, and
suggest new mechanisms that could be exploited therapeutically
in this life-limiting disease.
Methods
Ethics and patient selection. Cases were recruited from the UK National Pul-
monary Hypertension Centres, Universite Sud Paris (France), the VU University
Medical Center Amsterdam (The Netherlands), the Universities of Gießen and
Marburg (Germany), San Matteo Hospital, Pavia (Italy), and Medical University of
Graz (Austria). All cases had a clinical diagnosis of idiopathic PAH, heritable PAH,
drug-associated and toxin-associated PAH, or PVOD/PCH established by their
expert centre. The non-PAH cohort for the case-control comparison comprised
6385 unrelated subjects recruited to the NIHR BR-RD study. All PAH and non-
PAH patients provided written informed consent (UK Research Ethics Committee:
13/EE/0325), or local forms consenting to genetic testing in deceased patients and
non-UK cases. An additional UK family diagnosed with HPAH was ascertained as
described previously39. Blood and saliva samples were collected under written
informed consent of the participants or their parents for use in gene identiﬁcation
studies (UK Research Ethics Committee: 08/H0802/32).
Composition of non-PAH control cohort. The non-PAH control cohort consisted
of subjects with bleeding, thrombotic and platelet disorders (15.5%), cerebral small
vessel disease (2.1%), Ehlers-Danlos syndrome (0.3%), subjects recruited to
Genomics England Ltd (19.8%), hypertrophic cardiomyopathy (3.6%), intrahepatic
cholestasis of pregnancy (4.1%), Leber hereditary optic neuropathy (0.9%), multiple
primary tumours (7.8%), neuropathic pain disorder (2.6%), primary immune
disorders (15.3%), primary membranoproliferative glomerulonephritis (2.3%),
retinal dystrophies/paediatric neurology and metabolic disease (19.8%), stem cell
and myeloid disorders (2.1%), steroid resistant nephrotic syndrome (3.6%), and
others (0.3%), or their ﬁrst degree relatives.
High-throughput sequencing. DNA extracted from venous blood underwent
whole-genome sequencing using the Illumina TruSeq DNA PCR-Free Sample
Preparation kit (Illumina Inc., San Diego, CA, USA) and Illumina HiSeq 2000 or
HiSeq X sequencer, generating 100–150 bp reads with a minimum coverage of 15×
for ~95% of the genome (mean coverage of 35×). Whole-exome sequencing was
conducted for individual II-1 (Fig. 4a) using genomic DNA extracted from per-
ipheral blood. Paired-end sequence reads were generated on an Illumina HiSeq
2000.
Generation of analysis-ready data sets. Sequencing reads were pre-processed by
Illumina with Isaac Aligner and Variant Caller (v2, Illumina Inc.) using human
genome assembly GRCh37 as reference. Variants were normalised, merged into
multi-sample VCF ﬁles by chromosome using the gVCF aggregation tool agg
(https://github.com/Illumina/agg) and annotated with Ensembl’s Variant Effect
Predictor (VEP). Following read alignment to the reference genome (GRCh37),
variant calling and annotation of whole-exome data for individual II:1 were per-
formed using GATK UniﬁedGenotyper40 and ANNOVAR41, respectively. Anno-
tations included minor allele frequencies from other control data sets (i.e. ExAC42,
1000 Genomes Project43 and UK10K44) as well as deleteriousness and conservation
scores (i.e., CADD45, SIFT46, PolyPhen-247 and Gerp48) enabling further ﬁltering
and assessment of the likely pathogenicity of variants. To take forward only high
quality calls, the pass frequency (proportion of samples containing alternate alleles
that passed the original variant ﬁltering) and call rate (proportion of samples with
reference or alternate genotypes) were combined into the overall pass rate (OPR:
pass frequency × call rate) and variants with an OPR of 80% or higher were
retained.
Estimation of ethnicity and relatedness. We estimated the population structure
and relatedness based on a representative set of SNPs using the R package GEN-
ESIS to perform PC Air49 and PC Relate50, respectively. The selected 35,114
autosomal SNPs were present on Illumina genotyping arrays (HumanCoreExome-
12v1.1, HumanCoreExome-24v1.0, HumanOmni2.5–8v1.1), do not overlap quality
control excluded regions or multiallelic sites in the 1000 Genomes (1000 G) Phase 3
data set43, do not have any missing genotypes in NIHR BR-RD, had a MAF of 0.3
or above and LD pruning was performed using PLINK51 with a window size of 50
bp, window shift of 5 bp and a variance inﬂation factor threshold of 2. The
2,110 samples from the 1000 G Project including the European (EUR), African
(AFR), South Asian (SAS) and East Asian (EAS) populations (excluding the
admixed American population) were ﬁltered for the selected SNPs and the ﬁltered
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data were used to perform a principal component analysis (PCA) using PC Air. We
modelled the scores of the leading ﬁve principal components as data generated by a
population speciﬁc multivariate Gaussian distribution and estimated the corre-
sponding mean and covariance parameters. Genotypes from the NIHR BR-RD
samples were projected onto the loadings for the leading ﬁve principal components
from the 1000 G PCA and we computed the likelihood that each sample belonged
to each subpopulation under a mixture of multivariate Gaussians models. Each
sample was allocated to the population with the highest likelihood, unless the
highest likelihood was similar to likelihood values for other populations, as might
be expected for example under admixed ancestry or if the sample came from a
population not included in 1000 G. Such ambiguous samples were labelled as
“other”. PC Relate was used to to identify related individuals in NIHR BR-RD. We
used the ﬁrst 20 PCs from PC Air to adjust for relatedness and extracted the
pairwise Identity-By-State distances and kinship values. The pairwise information
was used by Primus to infer family networks and calculate the maximum set of
unrelated samples.
Of the 9110 NIHR BR-RD samples, we assigned 80.2% to Non-Finish European
(n= 7307), 7.2% to South Asian (n= 649), 2.3% to African (n= 213), 0.08% to
East Asian (n= 78), 0.02% to Finnish-European (n= 19) and 9.2% to Other (n=
844) and retrieved a maximum set of 7,493 unrelated individuals (UWGS10K),
representing 82.2% of the entire NIHR BR-RD cohort.
Cohort deﬁnition and allele frequency calculation. Based on the relatedness
analysis, we deﬁned the following sample subsets: (a) the maximum number of
unrelated non-PAH controls (UPAHC, n= 6385), (b) all affected PAH cases
(PAHAFF, n= 1048), and (c) all unrelated PAH index cases (PAHIDX,
n= 1038). These subsets were used to annotate the variants in the multi-sample
VCF ﬁle with calculated minor allele frequencies using the ﬁll-tags extension of
BCFtools52.
Rare variant ﬁltering. Filtering of rare variants was performed as follows: (1)
variants with a MAF less than 1 in 10,000 in UPAHC subjects, UK10K and ExAC
were retained (adjusted for X chromosome variants to 1 in 8000); (2) variants with
a combined annotation dependent depletion deleteriousness (CADD) score of less
than 15 were excluded. CADD scores were calculated using the CADD web service
(http://cadd.gs.washington.edu) for variants lacking a score; (3) premature trun-
cating variants (PTVs) or missense variants of the canonical transcript were
retained; 4) missense variants predicted to be both tolerated and benign by SIFT
and PolyPhen-2, respectively, were removed.
To identify likely causative mutations (as reported in Supplementary Table 3),
variants in previously reported and putative genes, identiﬁed in this study, were
examined in more detail to exclude variants that did not segregate in families
(where data available). Furthermore, variants shared between cases and non-PAH
controls, as well as variants of uncertain signiﬁcance that co-occurred with
previously reported causative mutations or high impact PTVs were also excluded.
Burden analysis of protein-truncating and missense variants. Filtered variants
were grouped per gene and consequence type (predicted PTV/missense) and
subjects with at least one variant were counted (no double counting) per group and
tested for association with disease. We applied a one-tailed Fisher’s exact test with
post hoc Bonferroni correction to calculate the P value for genome-wide
signiﬁcance.
Rare variant analysis using SKAT-O. To further investigate the aggregated effect
that rare variants contribute to PAH aetiology, we applied a Sequence Kernel
Association test (SKAT-O). SKAT-O increases the power of discovery under dif-
ferent inheritance models by combining variance-component and burden tests.
Variants were ﬁltered based on MAF as speciﬁed above, and only PTV and mis-
sense variants were included. For the analysis we implemented SKAT-O in RvTests
v1.9.953 with default parameters and weights being Beta(1,25), and applying a
correction for read length, gender and the ﬁrst ﬁve principal components of the
ethnicity PCA. Variants were collapsed considering only the protein-coding region
in the canonical transcript of the protein-coding genes in the genome assembly
GRCh37.
Analysis of large deletions. Copy number variation was identiﬁed using Canvas54
and Manta55. Deletions called by both Manta and Canvas with a reciprocal overlap
of ≥20% were retained. Of these, deletions were excluded if both failed standard
Illumina quality metrics or overlapped with known benign deletions in healthy
cohorts56. Deletions with a reciprocal overlap of ≥50% between samples were
merged and ﬁltered for a frequency of less than 1 in 1000 in WGS10K and
overlapping exonic regions of protein-coding genes (GRCh37 genome assembly).
The number of subjects with deletions were added up by gene (no double counting
of subjects) and tested for association with the disease. We applied a one-tailed
(greater) Fisher’s exact test with Bonferroni post hoc correction for multiple testing
to determine the P values for genome-wide signiﬁcance.
Conﬁrmation of variants. Variant sequencing reads for SNVs, indels and deletions
were visualised for validation on Integrative Genomes Viewer (IGV)57, and were
conﬁrmed by diagnostic capture-based high-throughput sequencing, if the IGV
inspection was not satisfactory. For the familial segregation analysis, linkage to the
BMPR2 locus was ﬁrst examined by microsatellite genotyping analysis. Mutation
screening of the BMPR2, ACVRL1, ENG, AQP1 and SOX17 genes was conducted
by capillary sequencing using BigDye Terminator v3.1 chemistry. All DNA frag-
ments were resolved on an ABI Fragment Analyzer (Applied Biosystems). All
primer sequences are listed in Supplementary Table 9. The family trees were drawn
using the R package FamAgg58.
Structural analysis of novel variants. The domain structures and the functional
groups of the novel PAH genes were plotted according to the entry in UniProtKB.
Clustal Omega was used for sequence alignment. Structural data were obtained
from RCSB Protein Data Bank and analysed according to published reports. Fig-
ures were generated using PyMOL Molecular Graphics System.
Production of pGDF2 wild type and variant proteins. The cloning of human
wild-type pro-GDF2 (pGDF2) in pCEP4 has been described previously59. Site-
directed mutagenesis was performed according to the manufacturer’s instructions
(QuickChange Site-Directed Mutagenesis Kit, Agilent Technologies). Mutations
were conﬁrmed by Sanger sequencing. HEK-EBNA cells were transfected with
plasmids containing either wild-type or mutant pGDF2 for 14 h. The transfecting
supernatant was removed and replaced with CDCHO media (Invitrogen) for
5 days to express the proteins. The conditioned media containing GDF2 and the
variants were collected and snap-frozen on dry-ice before being stored at −80 °C.
For each variant, conditioned media from three independent transfections were
collected for further characterisation.
GDF2 ELISA. High binding 96-well ELISA plates (Greiner, South Lanarkshire, UK)
were coated with 0.2 µg/well of mouse monoclonal anti-human GDF2 antibody
(R&D Systems, Oxfordshire, UK) in PBS (0.1 M phosphate pH7.4, 0.137 M NaCl,
2.7 mM KCl, Sigma) overnight at 4 °C in a humidiﬁed chamber. Plates were washed
with PBS containing 0.05% (v/v) Tween-20 (PBS-T), followed by blocking with 1%
bovine serum albumin in PBS-T (1% BSA/PBS-T) for 90 min at room temperature.
Recombinant human GDF2 standards (1–3000 pg/ml) or conditioned media
samples (100 µl/well of 1:30, 1:100, 1:300, 1:1000, 1:3000 and 1:10,000 dilutions)
were then added and incubated for 2 h at room temperature. After washing, plates
were then incubated with 0.04 µg/well biotinylated goat anti-human GDF2 (R&D
Systems) in 1% BSA/PBS-T for 2 h. Plates were washed, then incubated with
ExtrAvidin(r)-Alkaline phosphatase (Sigma) diluted 1:400 in 1% BSA/PBS-T for
90 min. Plates were washed with PBS-T followed by water. The ELISA was
developed with a colorimetric substrate comprising 1 mg/ml 4-Nitrophenyl phos-
phate disodium salt hexahydrate (Sigma) in 1M Diethanolamine, pH 9.8 con-
taining 0.5 mM MgCl2. The assay was developed in the dark at room temperature
and the absorbance measured at 405 nm.
Cell culture and treatments. Distal human pulmonary artery smooth muscle cells
(PASMCs) were cultured from explants dissected from lung resection specimens.
Small pulmonary arterioles (0.5 to 2 mm diameter) were dissected and divided into
small pieces before plating in T25 ﬂasks. Explants were left to adhere for 2 h and
then incubated in DMEM/20% FBS plus amino acids at
37 °C in 95% air/5% CO2 until PASMCs had formed conﬂuent monolayers. Cells
were then trypsinized, and for subsequent passages cells were maintained in
DMEM supplemented with 10% FBS. The cellular phenotype of PASMCs was
conﬁrmed by positive immunoﬂuorescence staining with anti-smooth muscle
speciﬁc alpha-actin (Clone IA4 Sigma-Aldrich; 1:100 dilution). The derivation of
human tissues and cells was approved by Papworth Hospital ethical review com-
mittee (Ref 08/H0304/56+ 5) and all subjects provided informed and written
consent.
Human blood outgrowth endothelial cells (BOECs) were derived from
40–80 ml of peripheral venous blood isolated from healthy subjects. The study was
approved by the Cambridgeshire 3 Research Ethics Committee (Ref 11/EE/0297),
and all subjects provided informed and written consent. BOECs were cultured
in 10% FBS supplemented with EGM-2MV (Life Technologies, Carlsbad, CA).
Cells were used between passages 4 and 860. The endothelial phenotype of
BOECs was determined by ﬂow cytometry for expression of endothelial surface
markers, as described previously25. Cells were routinely tested to exclude
mycoplasma infection.
Human pulmonary artery endothelial cells (PAECs) were purchased from
Lonza (Cat. No. CC-2530; Basel, Switzerland). Cells were maintained in EGM-2
with 2% FBS (Lonza). PAECs were used for experiments between passages 4 and 8.
For experiments cells were cultured in the presence of EBM-2 containing
Antibiotic-Antimycotic (Invitrogen, Renfrewshire, UK). Cells were routinely tested
to exclude mycoplasma contamination.
RNA preparation and quantitative reverse transcription-PCR. Total RNA was
extracted using RNeasy Mini Kit with DNAse digestion (Qiagen, West Sussex, UK),
according to the manufacturer’s instructions. cDNA was prepared from 1 µg of
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RNA using High Capacity Reverse Transcriptase kit (Applied Biosystems, Foster
City, CA). Quantitative PCR reactions employed MicroAmp optical 96-well reac-
tion plates (Applied Biosystems). 50 ng µl−1 cDNA was used with SYBR Green
Jumpstart Taq Readymix (Sigma-Aldrich), ROX reference dye (Invitrogen) using
custom made sense and anti-sense primers (all 200 nmol l−1). Primers for human
ACTB (encoding β-actin), AQP1, ATP13A3, B2M, HPRT and SOX17 were
designed using PrimerBLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/;
Supplementary Table 9). Reactions were ampliﬁed on a Quantstudio 6 Real-Time
PCR system (Applied Biosystems). The relative abundance of each target gene in
different cell lines was compared using the equation 2−(CtGOI-Ct3HK), where Ct3HK
corresponded to the arithmetic mean of the Cts for ACTB, B2M and HPRT for
each sample. For expression analysis of siRNA knockdown, the 2−(ΔΔCt) method
was used and fold expression determined relative to the DH1 control.
siRNA transfection. Prior to transfection, cells were preincubated in Opti-MEM-I
reduced serum media (Invitrogen) for 2 h before transfection with 10 nM siRNA
that had been lipoplexed for 20 min at RT with DharmaFECT1 (GE Dharmacon,
Lafayette, CO). Cells were then incubated with the siRNA/DharmaFECT1 com-
plexes for 4 h at 37 °C before replaced by full growth media. Cells were kept in
growth media for 24 h before further treatment. Knockdown efﬁciency was con-
ﬁrmed by mRNA expression or immunoblotting. For proliferation assays, parallel
RNA samples were collected both on day0 and day6, conﬁrming that ATP13A3
expression was reduced by >90% on Day 0 and still reduced by >70% at Day 6. For
all other assays, parallel RNA samples were collected on the day of the experiment
to conﬁrm knockdown, which was >90%. The siRNAs used were oligos targeting
ATP13A3 (SASI_Hs02_00356805) from Sigma-Aldrich and ON-TARGET plus
non-targeting Pool (siCP; GE Dharmacon).
Flow cytometric apoptosis assay. BOECs were plated 150,000/well into 6-well
plates and transfected with siATP13A3 or siCP lipoplexed with DharmaFECT1.
Cells were then serum-starved in EBM-2 (Lonza) containing 0.1% FBS and
A/A for 8 h before treating with EBM-2 and A/A containing either 0.1%FBS or 5%
FBS for another 24 h. Cells were then trypsinized and after washing with PBS,
stained using the FITC Annexin V Apoptosis Dectection Kit I (BD Biosciences).
For each condition, dual-staining of 5 µl FITC conjugated Annexin V and 5 µl
propidium iodide (PI) were added and incubated at room temperature for
15 min. For the single staining controls for compensation, either 5 µl FITC
Annexin V or 5 µl PI was added into non-transfected cells. All samples were
analysed on BD Accuri™ C6 Plus platform (BD Biosciences). Data were collected
and analysed using FlowJo software, with AnnexinV+/PI− cells deﬁned as early
apoptotic (Treestar).
Caspase-Glo 3/7 assay. BOECs were seeded at a density of 150,000/well into 6-
well plates and transfected with siATP13A3 or siCP lipoplexed with Dharma-
FECT1. For each condition, cells were trypsinized from 6-well plates and reseeded
in triplicates into a 96-well plate at a density of 15,000–20,000/well and left to
adhere overnight. Cells were quiesced in EBM-2 containing 0.1% FBS for 24 h
before treating with or without EBM-2 and A/A containing either 0.1% FBS or 5%
FBS for 16 h. For measuring caspase activities, 100ul Caspase-Glo® 3/7 Reagent
(G8091 Promega) was added into each well, incubated and mixed on a plate shaker
in the dark for 30 min at room temperature. The lysates were transferred to a
white-walled 96-well plate and luminescence was read in a GloMax® luminometer
(Promega).
Data availability. WGS data of PAH cases included in this manuscript and eligible
for public release according to the UK Research Ethics rules have been deposited in
the European Genome-phenome Archive (EGA) at the EMBL—European Bioin-
formatics Institute under accession number EGAD00001003423.
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